3. Results3.1. Effect of oxyresvera

3. Results
3.1. Effect of oxyresveratrol against clinical herpes simplex virus isolates by plaque reduction assay
The antiviral activities of oxyresveratrol against wild type HSV- 1 (KOS), wild type HSV-2 (Baylor186), ten clinical HSV-1 isolates and ten clinical HSV-2 isolates were examined by plaque reduction assays. As shown in Table 1, the values of IC50 of oxyresveratrol for wild-type HSV-1 (KOS), HSV-1 (7401H) and HSV-2 (Baylor186) were 24.3 ± 2.6, 22.3 ± 3.9 and 22.3 ± 3.8 lg/ml, respectively. The IC50 of oxyresveratrol for HSV-1 clinical isolates and HSV-2 clinical isolates were 20.9–29.5 and 22.2–27.5 lg/ml, respectively. The values of IC50 of ACV for wild-type HSV-1 (KOS), HSV-1 (7401H) and HSV-2 (Baylor186) were 0.09 ± 0.02, 0.31 ± 0.04 and 0.43 ± 0.04 lg/ml, respectively. The values of IC50 of ACV for HSV- 1 clinical isolates and HSV-2 clinical isolates were 0.07–0.19 and 0.11–0.36 lg/ml, respectively. There were no significant differ- ences among the IC50 (P > 0.05) of various isolates of HSV-1. The clinical isolates were similarly susceptible to oxyresveratrol.
3.2. Anti-HSV activity of oxyresveratrol in cream by plaque reduction assay
The anti-HSV activities of oxyresveratrol in cream formulation against HSV-1 (KOS) and HSV-2 (Baylor186) were examined by plaque reduction assays. As shown in Fig. 1, the values of IC50 of oxyresveratrol against HSV-1 (KOS) and HSV-2 (Baylor186) were 22.5 ± 3.4 and 25.0 ± 2.5 lg/ml in post-treatment assay (Fig. 1A) and 22.5 ± 2.5 and 25.0 ± 3.0 lg/ml in the inactivation-treatment assay (Fig. 1B), respectively.
3.3. Effect of cream formulation on non-infected Vero cells viability determined by MTT reduction assay
No cytotoxic effects of oxyresveratrol cream at concentration of 50lg/ml and cream base were observed (Fig. 2). The CC50 of